Volume 87, Issue 3, Pages (March 2015)

Slides:

Advertisements

Similar presentations

LDL cholesterol in CKD—to treat or not to treat?

Advertisements

Volume 81, Issue 5, Pages (March 2012)

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient Christoph Wanner,

Frederik Persson, Peter Rossing Kidney International Supplements

Anemia management in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis Patricia M.

Volume 83, Issue 3, Pages (March 2013)

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target Szu-Chun Hung, Der-Cherng Tarng Kidney International

Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan

Prehypertension and chronic kidney disease: the ox or the plow?

Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007 Joanna M. Smith, Susan A. Mott,

Reassessment of the care of the patient with chronic kidney disease

C-reactive protein and dialysis access

John P. Middleton, Patrick H. Pun Kidney International

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

Need for better diabetes treatment for improved renal outcome

Volume 72, Issue 10, Pages (November 2007)

Yasuhiro Hamada, Masafumi Fukagawa Kidney International

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Volume 70, Pages S21-S25 (December 2006)

Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Fu L. Luan, Diane E. Steffick,

Volume 75, Issue 10, Pages (May 2009)

Steven G. Coca, Swathi Singanamala, Chirag R. Parikh

Volume 72, Issue 6, Pages (September 2007)

Comorbidity and confounding in end-stage renal disease

D. Batlle, P. Ramadugu, M.J. Soler Kidney International

Acute myocardial infarction in patients with chronic kidney disease: how are the most vulnerable patients doing? Gautam R. Shroff, Charles A. Herzog

The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis Sai Subhodhini Reddy, Jean L. Holley

Volume 74, Issue 3, Pages (August 2008)

Volume 70, Issue 11, Pages (December 2006)

The epidemiology of chronic kidney disease

Use of vitamin D in chronic kidney disease patients

Volume 75, Issue 1, Pages (January 2009)

Pieter Evenepoel, Björn K. Meijers Kidney International

LDL cholesterol in CKD—to treat or not to treat?

Volume 74, Issue 8, Pages (October 2008)

The calcium–phosphorus in guidelines for CKD-MBD

Volume 81, Issue 5, Pages (March 2012)

Volume 73, Issue 12, Pages (June 2008)

Volume 76, Issue 6, Pages (September 2009)

Volume 81, Issue 6, Pages (March 2012)

Extracorporeal therapy in sepsis: are we there yet?

Tilman B. Drüeke, Ziad A. Massy Kidney International

Alternate-day dialysis may be needed for hemodialysis patients

Methods for guideline development

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Volume 87, Issue 1, Pages (January 2015)

Nephrology Crossword: Glomerulonephritis

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Will there be an epidemic of HIV-related chronic kidney disease in sub-Saharan Africa? Too soon to tell Kara K. Wools-Kaloustian, Samir K. Gupta Kidney.

Vitamin D in chronic kidney disease: is the jury in?

Volume 64, Issue 2, Pages (August 2003)

Cardio-Kidney-Damage: a unifying concept

Volume 72, Issue 2, Pages (July 2007)

Volume 80, Issue 10, Pages (November 2011)

Cardiovascular risk in chronic kidney disease

Volume 75, Issue 1, Pages (January 2009)

The hypothesis that abnormal BH4 metabolism impairs kidney function

Volume 86, Issue 2, Pages (August 2014)

Volume 75, Issue 7, Pages (April 2009)

Volume 88, Issue 5, Pages (November 2015)

Antioxidant therapy in hemodialysis patients: a systematic review

In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression B.O. Eriksen, O.C. Ingebretsen Kidney.

Rajni Singhal, Janet E. Hux, Shabbir M H Alibhai, Matthew J. Oliver

Stephen Pastan, J. Michael Soucie, William M. McClellan

Sugar-sweetened beverages and chronic disease

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Volume 87, Issue 3, Pages 649-659 (March 2015) Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes Vasilios Papademetriou, Laura Lovato, Michael Doumas, Eric Nylen, Amy Mottl, Robert M. Cohen, William B. Applegate, Zubin Puntakee, Jean Francois Yale, William C. Cushman Kidney International Volume 87, Issue 3, Pages 649-659 (March 2015) DOI: 10.1038/ki.2014.296 Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 1 Glycated hemoglobin levels with intensive and standard therapy in patients with or without chronic kidney disease (CKD). FU, follow-up; Int, intensive; Std, standard. Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 2 Rates for the primary and secondary outcomes in patients with and without chronic kidney disease (CKD). Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 3 Rates of primary and secondary outcomes by chronic kidney disease status. Rates for the primary and secondary outcomes in patients without CKD compared to patients with mild CKD I and II (a), CKD III (b) and albuminuria (c). Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 3 Rates of primary and secondary outcomes by chronic kidney disease status. Rates for the primary and secondary outcomes in patients without CKD compared to patients with mild CKD I and II (a), CKD III (b) and albuminuria (c). Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 4 Rates of primary and secondary outcomes by randomized treatment group (intensive versus standard). Rates for the primary and secondary outcomes with intensive versus standard glycemic therapy in patients with chronic kidney disease (CKD) (a) and non CKD (b). Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 5 Cardiovascular and all-cause mortality stratified by intensive or standard treatment group and by chronic kidney disease (CKD) status. Cardiovascular and all-cause mortality with intensive versus standard glycemic control in patients without CKD (a, c) and with CKD (b, d). Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions